Institutional Real Estate, Inc. Announces Acquisition of U.K.-based Lyndon Publishing 2 Limited
2.7.2025 19:44:00 EEST | Business Wire | Press release
Institutional Real Estate, Inc. (“IREI”) has completed its acquisition of the assets of London-based Lyndon Publishing 2 Ltd (“Lyndon Publishing”), which include The Property ChronicleandThe Green Chronicle.The former Lyndon Publishing 2 will now operate as a division of IREI.
The Property Chronicle reaches a global audience of real estate investment professionals, researchers, and academics. Its sister publication, The Green Chronicle, is edited to address the interests and concerns of emerging young talent in these real estate professions. Both publications are produced as weekly news briefings filled with original content and contributed feature articles from industry thought and opinion leaders. In addition, The Property Chronicle is also published as a quarterly, illustrated full-color magazine available in both digital and print formats, while The Green Chronicleis published exclusively in digital format. Together, the two publications reach approximately 50,000 professionals across the real estate, real assets, and broader investment communities in the U.K., EU, Middle East, Americas, and Asia Pacific regions, nearly doubling the circulation and reach of IREI’s existing publications and newslines.
As part of the acquisition, Stephen Yorke, founder of Lyndon Publishing, will join IREI as a consultant and will continue to serve as the editor of these two publications in that capacity. Yorke brings extensive experience in publishing and investment, having held roles at D&GAM, UBS Warburg, and JPMorgan Chase in London. He is also the founder of The Academy of Real Assets, a U.K.-based social enterprise that introduces students to career opportunities in real asset investing and investment management.
“The Property Chronicle has been my life for the last eight years and I would not have dreamed of selling, or parting with it, unless I had 100% confidence that IREI has the skill, resource and ambition to grow it as a global title and to serve our growing readers through live events and stimulating content. In an era when AI is everywhere, original, stimulating, thought-provoking human content will become more and more valued. I can’t wait to start working with IREI to keep The Property Chronicle at the forefront of Real estate and Real assets’ publishing,” commented Yorke.
“We are delighted to welcome Stephen and Lyndon Publishing to the IREI family,” commented Geoffrey Dohrmann, Chairman, CEO, and Editor-in-Chief of IREI. “Stephen’s values and the mission of his two publications are perfectly aligned with IREI’s core values and mission. The completion of this transaction enables us to support and expand our platforms in Europe, the Middle East and the Asia Pacific regions. The opportunities for synergy between our two platforms are immense.”
About Institutional Real Estate, Inc.
Founded in 1987, Institutional Real Estate, Inc. (IREI) is an investor-focused global media firm long recognized as a critical nexus for sharing reliable industry intelligence, research and insights across the institutional real estate investment, infrastructure investment and private wealth advisory marketplaces. Through its suite of publications, industry events, IRE.IQ database, as well as its sponsorship programs and consulting services, IREI provides timely information and strategic advice to investors, investment managers, consultants, private wealth advisers and other key investment industry stakeholders. For more information, visit www.irei.com.
About Lyndon Publishing 2 Ltd
Founded in 2017, Lyndon Publishing 2 Ltd is the publisher of The Property Chronicle and The Green Chronicle, two well-respected platforms offering thought and opinion leadership covering issues impacting participants in the real estate, real assets, and the broader investment community. Launched in 2024, The Green Chronicle is a quarterly publication that serves as the voice of the next generation, featuring contributions from the under 35 set around the globe, with articles focused on sustainability, ESG, and innovation across the asset classes. Together, the publications engage a contributor base of over 300 industry professionals and academics, while serving a global audience comprised of approximately 50,000 readers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250702208153/en/
Contacts
Media Contact:
Sandy Terranova
Institutional Real Estate, Inc.
925-244-0500
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom